tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Masutani K et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. 2014 Transplant. Proc. pmid:24655972
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Spinelli GA et al. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. 2011 Transplant. Proc. pmid:22172836
Soda M et al. Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Transplant. Proc. pmid:28736028
Mac Guad R et al. Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:26915847
Herrero JC et al. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. 2002 Transplant. Proc. pmid:11959201
Facundo C et al. Results of a triple induction regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. 2002 Transplant. Proc. pmid:11959203
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Fraile P et al. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715943
Lauro A et al. Results of intestinal and multivisceral transplantation in adult patients: Italian experience. 2006 Jul-Aug Transplant. Proc. pmid:16908252
Ueno T et al. Renal dysfunction following adult intestinal transplant under tacrolimus-based immunosuppression. 2006 Jul-Aug Transplant. Proc. pmid:16908274
Oltean M et al. Transplantation of preconditioned intestinal grafts is associated with lower inflammatory activation and remote organ injury in rats. 2006 Jul-Aug Transplant. Proc. pmid:16908278
Burkhalter F et al. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. 2012 Transplant. Proc. pmid:23195006
Luk JM et al. Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-stimulated human monocytes. 2000 Transplant. Proc. pmid:11120045
Bora F et al. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients. 2012 Transplant. Proc. pmid:23195020
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
Charco R et al. Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation. 2005 Transplant. Proc. pmid:16386588
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Crespo-Leiro MG Calcineurin inhibitors in heart transplantation. 2005 Transplant. Proc. pmid:16386614
Farghali H et al. A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. 1991 Transplant. Proc. pmid:1721284
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Nishikawa S et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. 2009 Transplant. Proc. pmid:19917404
Sathyan S et al. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. 2009 Transplant. Proc. pmid:19917422
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Pérez-Flores I et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. 2010 Transplant. Proc. pmid:20970565
Marzoa-Rivas R et al. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. 2010 Transplant. Proc. pmid:20970591
Marzorati S et al. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. 2009 Jan-Feb Transplant. Proc. pmid:19249555
Lodewijk L et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. 2009 Jan-Feb Transplant. Proc. pmid:19249561
Nardo B et al. Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. 1994 Transplant. Proc. pmid:7518112
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Florman S et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848672
Wiesner RH et al. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. 1993 Transplant. Proc. pmid:7682352
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Chen J et al. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. 2008 Transplant. Proc. pmid:18589119
Wynn C et al. High level of TGF-beta in organ transplantation might be due to rejection rather than calcineurin inhibitor medication. 2002 Transplant. Proc. pmid:12176408
Marcén R et al. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. 2006 Transplant. Proc. pmid:17097957
Mortensen DM et al. Calcineurin activity in tacrolimus-treated renal transplant patients early after and 5 years after transplantation. 2006 Transplant. Proc. pmid:17098028
Borrows R et al. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results. 2005 Transplant. Proc. pmid:15919468
Loucaidou M et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. 2005 Transplant. Proc. pmid:15919469
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Rabkin JM et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. 2002 Transplant. Proc. pmid:12176483
Langrehr JM et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. 2002 Transplant. Proc. pmid:12176487
Lyne JC et al. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. 1997 Feb-Mar Transplant. Proc. pmid:9123015
Zucker K et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123027
Iaria G et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. 2011 Transplant. Proc. pmid:21620043
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Yin DP et al. Efficacy of FK506, leflunomide, anti-CD4, and CTLA4IG treatments in rat to mouse pancreas xenograft transplantation. 2000 Transplant. Proc. pmid:10936320
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Witzigmann H et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. 2002 Transplant. Proc. pmid:12493472
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Citterio F et al. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up. 2002 Transplant. Proc. pmid:12176535
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Kim JD et al. Single-Center Experience of ABO-Incompatible Living-Donor Liver Transplantation With a New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score-Matching Analysis. 2016 Transplant. Proc. pmid:27320573
Hariharan S et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123462
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Alessiani M et al. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus. 2000 Transplant. Proc. pmid:10995915
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Ricordi C et al. Human islet allotransplantation under FK 506. 1991 Transplant. Proc. pmid:1721410
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Beck Y and Akiyama N Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. 1989 Transplant. Proc. pmid:2472695
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
Baran DA et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. 2002 Transplant. Proc. pmid:12176609
Zhou S et al. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. 2011 Transplant. Proc. pmid:21911157
Kauffman HM et al. Drug regimens affect cadaveric kidney graft survival. 2001 Feb-Mar Transplant. Proc. pmid:11267176
Hummel AD et al. Application of artificial neural networks in renal transplantation: classification of nephrotoxicity and acute cellular rejection episodes. 2010 Transplant. Proc. pmid:20304167
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Li ZY et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. 2010 Transplant. Proc. pmid:21168731
Grabczewska Z et al. Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index. 2013 Transplant. Proc. pmid:23726621
Renner FC et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. 2013 Transplant. Proc. pmid:23726630
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Lautenschlager I et al. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. 1991 Transplant. Proc. pmid:1714650
Suarez Benjumea A et al. Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication. 2016 Transplant. Proc. pmid:27932111
Rodriguez Cubillo B et al. Risk Factors of Recurrence of Diabetic Nephropathy in Renal Transplants. 2016 Transplant. Proc. pmid:27932117
Rathi M et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. 2015 Transplant. Proc. pmid:26036543
Mohsin N et al. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus. 2015 Transplant. Proc. pmid:26036534
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503